Research Use Only Notice: This article discusses BPC-157 only in the context of controlled in-vitro cell experiments, ex-vivo laboratory tests, and controlled experimental animal models. It does not provide instructions for personal use, administration, dosing, medical treatment, veterinary treatment, or any other non-research application.
The U.S. Food and Drug Administration states that it does not have enough safety information to determine whether compounded BPC-157 may harm humans. The agency also notes possible risks related to immune reactions, peptide-related impurities, and difficulties in fully characterizing the active pharmaceutical ingredient.[1]
The World Anti-Doping Agency’s 2026 Prohibited List includes BPC-157 under category S0, Non-Approved Substances, prohibited at all times in sport.[2]
BPC-157 is a synthetic peptide made of 15 amino acids. Most published research on it has used cultured cells, isolated tissues, or controlled experimental animal models.
Researchers have reported changes in several signaling pathways linked to cell movement, blood-vessel-related activity, and cell survival. However, these findings do not yet form one complete and fully confirmed mechanism.[3][4]
This article explains what the main studies found, what those findings may mean, and what they do not prove.

Basic Peptide Information
| Property | Value |
|---|---|
| Amino acid sequence | GEPPPGKPADDAGLV |
| Number of amino acids | 15 |
| Molecular formula | C62H98N16O22 |
| Average molecular weight (free peptide) | Approximately 1,419.55 g/mol for H-GEPPPGKPADDAGLV-OH; monoisotopic exact mass approximately 1,418.7042 Da. Counterion and hydration state are batch-dependent and are not represented by these values.[3] |
| CAS Registry Number | 137525-51-0 |
| Proline pattern | Three consecutive prolines at positions 3–5, with another proline at position 8 |
These identity data are listed in PubChem.[3] The sequence contains four proline residues in total, but only three are consecutive.
Residue 2 is glutamic acid, not proline.
The stable three-dimensional structure of BPC-157 in solution has not been fully established. It should therefore not be described as having a confirmed polyproline helix or a proven SH3-domain-binding structure unless direct structural evidence becomes available.
What Researchers Mean by a Signaling Pathway
Cells respond to outside signals through proteins that pass information from one step to the next. A study may show that one or more of these proteins become more active after exposure to a peptide.
This can suggest that a pathway is involved.
However, a change in a signaling protein does not automatically prove that the peptide binds directly to that protein. Direct binding normally requires separate tests designed to measure a physical interaction.
VEGFR2, Akt, and eNOS
VEGFR2 is a receptor found on vascular endothelial cells. These cells line the inside of blood vessels.
Akt and eNOS are proteins that work farther down the same signaling route. eNOS helps cells produce nitric oxide, a signaling molecule involved in blood-vessel function.
A 2017 study examined cultured vascular endothelial cells, a chick chorioallantoic membrane model, and a standardized rat hind-limb ischemia model. The researchers reported higher VEGFR2 mRNA and protein expression after BPC-157 exposure.
They also observed VEGFR2 internalization and changes in Akt and eNOS phosphorylation.[5]
The same study used dynasore, a compound that interferes with cell-membrane internalization. Dynasore reduced VEGFR2 internalization, signaling through Akt and eNOS, and the formation of tube-like networks by endothelial cells.
Dynasore is not a fully specific test of VEGFR2 endocytosis; independent studies have shown that it can suppress VEGFR2 signaling through endocytosis-independent effects. The experiment therefore supports pathway involvement but does not establish that receptor internalization itself is the necessary causal event.[5]
These results support the involvement of VEGFR2-related signaling. They do not prove that BPC-157 directly binds to VEGFR2.
The study measured changes in receptor expression, movement, and signaling, but it did not provide a direct peptide-to-receptor binding measurement.
Src, Caveolin-1, and eNOS
Another study looked at a different route that may affect nitric oxide signaling. This route involves Src, caveolin-1, and eNOS.
Caveolin-1 can hold eNOS in a less active state. Changes in caveolin-1 may release eNOS and allow more nitric oxide-related activity.
In a 2020 study using cultured endothelial cells and isolated rat aortic rings, researchers reported changes in Src, caveolin-1, and eNOS phosphorylation after BPC-157 exposure. They also reported higher nitric oxide-related fluorescence and relaxation of isolated blood-vessel tissue.
Blocking nitric oxide signaling reduced the relaxation response.[6]
The researchers also found less association between caveolin-1 and eNOS after BPC-157 exposure. This supports a possible role for the Src–caveolin-1–eNOS pathway in the tested systems.[6]
This pathway should not be called completely independent of VEGFR2. The published experiments did not directly remove VEGFR2 and then show that the full Src-related response remained unchanged.
FAK and Paxillin
FAK and paxillin are proteins involved in cell attachment and movement. They help cells connect to the surface around them and reorganize their internal support structure.
A 2011 study used rat tendon explants and tendon-derived fibroblasts. BPC-157 exposure was associated with greater fibroblast outgrowth from tendon tissue, better cell survival under oxidative stress, more movement through a Transwell membrane, and greater cell spreading.
Phosphorylation of FAK and paxillin increased, while the total amounts of these proteins did not change.[7]
These findings suggest that FAK and paxillin may help explain the cell-movement response in this tendon-derived model. They do not show that BPC-157 binds directly to FAK or that the same pathway controls every effect in every cell type.
ERK1/2 Signaling
ERK1/2 is part of a common signaling system that helps control cell activity, movement, and division.
A 2015 study examined human umbilical vein endothelial cells (HUVECs). The researchers reported higher MTT assay signals, more cell movement, more tube-like network formation, higher VEGF-A expression, and increased ERK1/2 phosphorylation after BPC-157 exposure.
The study also reported changes in the signaling-related proteins c-Fos, c-Jun, and Egr-1. PD98059, an inhibitor used to reduce MEK–ERK signaling, lowered several of the measured responses.[8]
This supports the involvement of ERK1/2 under the study conditions, but it does not prove that ERK1/2 is the only pathway involved or that it sits directly below FAK in a single BPC-157 signaling chain—the FAK and ERK findings came from different experimental systems.
FBXO22 and BACH1
A 2026 study reported a more specific intracellular interaction involving FBXO22 and BACH1. FBXO22 helps mark certain proteins for breakdown inside cells.
BACH1 is a protein that controls the activity of several genes and has been reported as an inhibitor of angiogenesis in other biological settings.[9]
The researchers used a tagged form of BPC-157, protein-capture methods, mass spectrometry, immunoprecipitation, ELISA, and surface plasmon resonance (SPR). These tests supported a direct interaction between BPC-157 and FBXO22 in the laboratory system.
The study found that proline at position 3 was important for this interaction; when that proline was replaced with alanine, the modified peptide no longer showed the same FBXO22 binding or the same cell-assay responses.[9]
The researchers also reported that the BPC-157–FBXO22 interaction reduced the breakdown of BACH1. BACH1 protein increased, even though BACH1 messenger RNA did not, suggesting that the change occurred mainly at the protein-stability level.[9]
FBXO22 and BACH1 knockdown differ in direction. FBXO22 knockdown by itself increased CCK-8 assay signals and tube-like network formation, while adding BPC-157 produced no clear additional increase.
This is consistent with BPC-157 functionally opposing FBXO22 in the tested system. By contrast, BACH1 knockdown reduced the BPC-157-associated CCK-8 signals, tube-like network formation, and expression of several angiogenesis-related factors.[9]
BACH1 has been reported as an inhibitor of angiogenesis in other biological settings. The 2026 study therefore proposes a context-dependent role in which BACH1 stabilization may promote the expression of selected angiogenesis-related genes under the tested endothelial and redox conditions.
This apparently opposite behaviour remains mechanistically unresolved and requires independent replication.[9]
Study limitations to note. The SPR and recombinant-protein assays provide stronger evidence for a direct interaction than the earlier pathway studies.
However, the source paper contains inconsistent descriptions of the SPR concentration range—the figure legend specifies 23.44–96,000 nM, whereas the methods section lists 1.89–31.25 nM, a discrepancy of several thousand-fold. The reported KD values should therefore be interpreted cautiously until the experimental details are clarified or independently reproduced.
In addition, the main HUVEC concentration experiments used BPC-157 in the microgram-per-milliliter range, whereas the alanine-mutant functional experiment was reported at 10 ng/mL; these concentrations differ by several orders of magnitude, and the unit and experimental comparability require clarification.[9]
The 2026 study’s methods section also did not clearly report the purity, salt form, or batch-specific impurity data for the BPC-157 and mutant peptides, which limits the ability to assess whether batch-related variables may have influenced the binding and cell-assay results.
How the Findings Fit Together
The VEGFR2, Src, FAK, ERK1/2, and FBXO22 studies were not all performed in the same cells or under the same conditions. Some used endothelial cells, some used tendon-derived fibroblasts, and others used isolated tissues or laboratory animal models.
The pathways may overlap, but current evidence does not show one confirmed sequence in which BPC-157 activates all of them in a fixed order. It is more accurate to describe them as separate signaling findings reported in different research models.
The FBXO22–BACH1 study may explain part of the endothelial response, but it does not yet explain every earlier finding involving VEGFR2, Src, eNOS, FAK, or ERK1/2.
VEGF-A results across studies are not consistent. The 2015 HUVEC study reported increased VEGF-A expression after BPC-157 exposure, whereas the 2017 endothelial-cell study reported increased VEGFR2 mRNA and protein expression without a corresponding increase in VEGF-A.
The discrepancy may reflect differences in concentration, exposure time, assay method, culture conditions, or peptide-batch characteristics, but it has not yet been resolved experimentally.[8][5]
What the Laboratory Tests Actually Measure
- MTT and CCK-8 assays: These tests mainly measure metabolic activity in viable cells. A higher signal may be related to more living cells, higher metabolism per cell, or both. It should not automatically be described as a direct cell count or definite proof of cell division.[10]
- Scratch assays: These tests measure how quickly a gap in a cell layer closes. Gap closure can be affected by both cell movement and cell division, so the two effects should be separated when possible.[11]
- Tube-formation assays: Endothelial cells can form short-lived, tube-like networks on a laboratory gel. This is a useful in-vitro test of angiogenesis-related behavior, but it does not prove that mature and functional blood vessels have formed.[12]
- Phosphorylation tests: These tests show that the activity state of a signaling protein has changed. They do not, by themselves, show that BPC-157 physically binds to that protein.
- Inhibitor experiments: If an inhibitor lowers a response, the blocked pathway may be involved. However, inhibitors can affect more than one target, so genetic tests and direct binding studies provide stronger support.
Limits of the Current Evidence
Most BPC-157 research remains preclinical. Cell experiments and controlled experimental animal models can help researchers study possible mechanisms, but they cannot establish safety or effectiveness for human or veterinary use.
The published studies also use different cell types, test methods, exposure times, peptide batches, and outcome measures. This makes it difficult to combine all findings into one simple mechanism.
A 2025 narrative review focused on musculoskeletal healing concluded that the available evidence remained predominantly preclinical and that stronger independent studies are needed.[4]
Important unanswered questions include:
- Whether other laboratories can repeat the FBXO22–BACH1 findings.
- How BPC-157 enters endothelial cells and reaches FBXO22.
- Whether VEGFR2 changes occur directly or through another upstream protein.
- How the VEGFR2, Src, FAK, ERK1/2, and FBXO22 pathways relate to each other in the same cell model.
- Whether the findings remain consistent across independently produced and fully characterized peptide batches.
- Whether short-term cell-assay findings remain present in longer and more complex laboratory models.
Conclusion
Laboratory research has linked BPC-157 exposure to several signaling systems, including VEGFR2–Akt–eNOS, Src–caveolin-1–eNOS, FAK–paxillin, ERK1/2, and FBXO22–BACH1.
The VEGFR2, Src, FAK, and ERK1/2 studies mainly show pathway association. They do not prove that BPC-157 directly binds to those proteins.
The 2026 FBXO22 study provides more direct binding evidence and suggests that BPC-157 may increase BACH1 protein stability in endothelial cells. The BACH1 stabilization mechanism is notable because BACH1 has been reported as an inhibitor of angiogenesis elsewhere; a context-dependent reversal of this role under the tested conditions remains mechanistically unresolved.
Even so, the result needs independent confirmation, particularly given the inconsistencies in the reported SPR concentration range and the large difference between the P3A mutant and general HUVEC concentration settings.
The most accurate current conclusion is that several possible mechanisms have been identified in preclinical models, but the complete mechanism of BPC-157 is not yet settled.
Sources
- U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks.
FDA official source. - World Anti-Doping Agency. 2026 Prohibited List (effective 1 January 2026). BPC-157 listed under S0, Non-Approved Substances, prohibited at all times.
WADA official source. - National Center for Biotechnology Information. PubChem Compound Summary for CID 9941957, BPC-157 (C62H98N16O22, avg 1,419.5 g/mol, monoisotopic 1,418.70415882 Da, CAS 137525-51-0).
PubChem record. - McGuire FP, Martinez R, Lenz A, Skinner L, Cushman DM. Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing. Curr Rev Musculoskelet Med. 2025;18(12):611-619. PMID: 40789979.
PubMed record. - Hsieh MJ, Liu HT, Wang CN, et al. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation. J Mol Med. 2017;95(3):323-333. PMID: 27847966.
PubMed record. - Hsieh MJ, Lee CH, Chueh HY, et al. Modulatory effects of BPC 157 on vasomotor tone and the activation of Src-Caveolin-1-endothelial nitric oxide synthase pathway. Sci Rep. 2020;10:17078. PMID: 33051481.
PubMed record. - Chang CH, Tsai WC, Lin MS, Hsu YH, Pang JHS. The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration. J Appl Physiol. 2011;110(3):774-780. PMID: 21030672.
PubMed record. - Huang T, Zhang K, Sun L, et al. Body protective compound-157 enhances alkali-burn wound healing in vivo and promotes proliferation, migration, and angiogenesis in vitro. Drug Des Devel Ther. 2015;9:2485-2499. PMID: 25995620.
PubMed record. - Zhang J, Liu M, Ou H, et al. BPC157 drives angiogenesis through FBXO22-dependent stabilization of BACH1. Cell Commun Signal. 2026;24:149. PMID: 41606641. PMC12947506.
PubMed record. - Riss TL, Moravec RA, Niles AL, et al. Cell Viability Assays. Assay Guidance Manual. National Center for Advancing Translational Sciences.
NCBI Bookshelf. - Molinie N, Gautreau A. Directional Collective Migration in Wound Healing Assays. Methods Mol Biol. 2018;1749:11-19. PMID: 29525986.
PubMed record. - Arnaoutova I, George J, Kleinman HK, Benton G. The endothelial cell tube formation assay on basement membrane turns 20: state of the science and the art. Angiogenesis. 2009;12(3):267-274. PMID: 19399631.
PubMed record.
Research Use Only Disclaimer
Research Use Only: The BPC-157 product described on this page is supplied for laboratory research use only and is not intended for human or veterinary use. This article is provided for informational context regarding published preclinical research findings and general analytical considerations, and does not constitute medical, clinical, veterinary guidance or treatment advice.